CXG 87
Alternative Names: budesonide/formoterol dry powder inhalation - Hangzhou Chance Pharmaceutical; CXG-87Latest Information Update: 09 Jan 2026
At a glance
- Originator Hangzhou Chance Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 09 Oct 2025 Hangzhou Chance Pharmaceuticals enters commercial cooperation agreement with Huadong Medicine for CXG 87 in China
- 09 Oct 2025 Phase-III clinical trials in Asthma in China (Inhalation) before October 2025
- 09 Oct 2025 Phase-III clinical trials in Chronic obstructive pulmonary disease in China (Inhalation) before October 2025